Ph + ALL

Related by string. * PHS . ph . Phd . PHED . phd . pHs : Christo pher . diagnosed Ph + . soil pH . Ph + CML . neutral pH . MD PhD / + - [008] . + - [003] . + - [027] . + - [020] . + - [007] . + - [017] : + S europe . Average + -1 . + input switcher . Crispin Porter + Bogusky . assigned BBB + / alls . Aller . all . Alling . Alls : IN ALL CAPS . WARRANTIES PARTS OR ALL . ALL THAT REMAINS . All Star . All Rights Reserved * *

Related by context. Frequent words. (Click for all words.) 73 Ph + CML 70 chronic myeloid leukemia CML 63 dasatinib 63 nilotinib 62 imatinib 62 myelodysplastic syndromes 61 metastatic renal cell carcinoma 60 FOLFOX 60 chronic lymphocytic leukemia CLL 60 hypercalcemia 60 glioblastoma multiforme GBM 60 myelofibrosis 60 fludarabine 60 acute myeloid leukemia AML 60 HGS ETR1 60 unresectable 60 lupus nephritis 60 cutaneous T cell 59 tyrosine kinase inhibitors 59 chemotherapy regimens 59 resistant ovarian cancer 59 biologic therapy 59 vandetanib 58 limiting toxicity 58 B CLL 58 5 fluorouracil 58 systemic lupus erythematosus 58 carboplatin 58 BCR ABL 58 febrile neutropenia 57 sunitinib 57 TORISEL 57 DMARDs 57 systemic lupus erythematosus SLE 57 cytarabine 57 relapsing remitting multiple sclerosis 57 mg BID 57 hematologic 57 evaluable patients 57 azacitidine 56 relapsed multiple myeloma 56 hematologic malignancies 56 evaluable 56 relapsing remitting MS 56 relapsing remitting 56 vinorelbine 56 mg/m2 56 temozolomide 56 mCRC 56 hormone refractory prostate cancer 55 bone metastases 55 CA4P 55 events AEs 55 adalimumab 55 hepatocellular carcinoma 55 refractory multiple myeloma 55 SPRYCEL 55 IMGN# 55 castration resistant prostate cancer 55 androgen independent 55 myelodysplastic syndromes MDS 55 5 FU 55 peginterferon alfa 2a 55 bortezomib 55 HRPC 55 mitoxantrone 55 severe renal impairment 54 plus ribavirin 54 infliximab 54 Phase 2a trial 54 bosentan 54 metastatic colorectal cancer 54 dose limiting toxicities 54 discontinuations due 54 allogeneic stem cell 54 humanized monoclonal antibody 54 NNRTI 54 soft tissue sarcomas 54 topotecan 54 anti rheumatic 54 gefitinib 54 refractory 54 follicular lymphoma 54 monotherapy 54 solid tumors 54 ACTEMRA 54 TREANDA 54 chemotherapeutic agent 54 hematologic cancers 54 hematological 54 etoposide 54 follicular non 54 RRMS 54 fluorouracil 54 ofatumumab 53 hematological cancers 53 chronic myelogenous leukemia 53 malignant gliomas 53 RECIST criteria 53 Phase 1b clinical 53 anticancer agents

Back to home page